The anti‐HER2 antibody, trastuzumab, has proven to be an effective targeted therapy, showing significant efficacy in the treatment of HER2‐positive breast cancer,46 gastric cancer,47 and gastroesophageal (GE) junction adenocarcinoma.48 Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.